Zolpidem, an imidazopyridine drug that affects the gamma-aminobutyric acid receptor, is typically used as a hypnotic sedative. It has been reported that this drug improves motor symptoms in patients with various movement disorders, including Parkinson disease. We presented a patient with advanced Parkinson disease who demonstrated improved akinesia after taking zolpidem without sleep induction or consciousness changes.
INTRODUCTION
Zolpidem is a short-acting hypnotic drug that is commonly used to treat insomnia. Its agonist action at the alpha subunit of the gamma-aminobutyric acid (GABA) receptor is implicated in its sedative, anticonvulsant, and anxiolytic properties 1) . Zolpidem does not cause structural changes in sleep, and it has little effect on cognitive function or motor skills; hence, it is suitable for treating insomnia in the elderly 2) . Although there is a lack of precise evidence of the action mechanism, Jankovic reported that GABAnergic enhancement may lead to impro-ved motor symptoms of Parkinson disease (PD) 3) . Subsequently, other studies indicated that zolpidem is effective in improving motor dysfunction in movement disorders including PD [4] [5] [6] . We present a patient with advanced PD who showed dramatic improvement in her motor symptoms soon after taking zolpidem, which had initially been prescribed for insomnia.
CASE REPORT
A 71-year-old female patient with PD was admitted to Kosin University Gospel Hospital. She had been diagnosed with PD at a local clinic 6 years prior to admission and was on a regimen of ropirinole 11.25 mg and trihexine 9 mg per day. A month prior to admission, she had started to complain of the persecutory delusion that her husband was trying to kill her and the distorted sensation that her saliva was dissolving her tongue. At admission, her vital signs were stable and routine blood tests were within normal limits. Her unified Parkinson disease rating scale (UPDRS) motor score was 68. Drug-induced psychosis was suspected, and her regimen was changed to gradually increase her dosage of levodopa from 300 to 900 mg. Though her UPDRS motor score showed 10% improvement, the persecutory delusion and tongue paresthesia persisted, and quetiapine 100 mg was prescribed; subsequently, both the delusion and the paresthesia gradually improved. Because the patient complained of continuous insomnia, zolpidem 5 mg was added. Her sleep symptoms were alleviated, and she was subsequently discharged.
At 1-week follow-up in the outpatient clinic, the patient's daughter reported that her mother felt well after taking zolpidem; within 30 minutes of taking it, her motor activity improved sufficiently that she was able to get up, do housework, eat and talk well. This apparent effect of zolpidem seemed to last for around 4 hours, after which she gradually returned to her prezolpidem state; her other medications were unchanged. The patient accordingly took zolpidem during the daytime, with the same dramatic but transient improvement. Her levodopa dosage was then increased to 1,200 mg per day and zolpidem was stopped, to ascertain whether the improvement was attributable to the levodopa rather than the zolpidem. Increasing the levodopa did not improve the patient's akinesia; a dramatic improvement was seen only after zolpidem was reintroduced. The patient was administered the UPDRS before and after the administration of 10 mg of zolpidem (Table 1) . She requested a continual prescription of zolpidem and was given a dosage of 5 mg thrice a day that did not cause significant somnolence.
DISCUSSION
Zolpidem is a selective GABA type A agonist that binds to the GABA-benzodiazepine receptor complex 1, 2) . The binding receptors of zolpidem are abundant in the globus pallidus interna (Gpi) and substantia nigra pars reticulata (SNpr), which are output structures of the cortical-basal ganglia-thalamo-cortical circuit 1, 3, 4) . Some authors have reported that the subthalamic nucleus (STN) has a high density of zolpidem-binding receptors that contain the α1 subunit 5) . Hypokinesia is the predominant functional effect of reduced dopamine input from the substatia nigra pars compacta to the striatum via the direct neurotransmitter pathway, which reduces the inhibitory activity of the Gpi and, consequently, increases the inhibition of the thalamic nuclei; this in turn reduces input to the cortical motor system. Furthermore, in this cortical-basal gangliathalamic circuit, there is much evidence to support the function of STN in various movement disorders; it sends the excitatory neurotransmitter glutamate to the Gpi, which triggers GABAnergic inhibitory activity 5, 6) . Theoretically, zolpidem activates selective GABA-nergic inhibitory neurons in the Gpi and SNpr, and thus, this mechanism should restore the thalamus and motor cortex. By another mechanism, decreased subthalamic excitatory signals by zolpidem decrease the GABAnergic inhibitory neurotransmitter of the Gpi and subsequently induce an excitatory thalamic effect in the cortical motor system 7) . In our patient, this effect may have led to the transient improvement after she took zolpidem.
Antioxidant and neuroprotective effects of zolpidem are also possible mechanisms related to improved akinesia. The results of a previous study suggested that these effects of zolpidem prevent oxidative damage to the brain and, consequently, certain abnormal movement disorders 8, 9) . In this case, however, because the akinesia improved immediately after zolpidem administration and continued only for several hours, the antioxidant and neuroprotective effects are less likely to have contributed to the improvement. However, more time is required to observe the neuroprotective effects of zolpidem.
Some researchers have contradicted the reports of the positive effects of zolpidem because it is a risk factor for PD 10, 11) . Although there was no exact mechanical evidence, these authors asserted that the prevalence of PD increased with increasing dosages of zolpidem because zolpidem is responsible for the onset of PD. Zolpidem is considered to have a relatively low abuse risk compared with benzodiazepines. However, long-term use at high doses increases the possibility of addiction, and thus, patients should be carefully monitored by their physicians 12) . Here, we reported a case of a PD patient who showed
